<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">DVD</journal-id>
<journal-id journal-id-type="hwp">spdvd</journal-id>
<journal-title>British Journal of Diabetes &amp; Vascular Disease</journal-title>
<issn pub-type="ppub">1474-6514</issn>
<issn pub-type="epub">XXXX-XXXX</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1474651412465441</article-id>
<article-id pub-id-type="publisher-id">10.1177_1474651412465441</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Achieving Best Practice</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Refractory hypoglycaemia in diabetes: a quinolone link</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Swaminathan</surname><given-names>Krishnan</given-names></name>
<xref ref-type="aff" rid="aff1-1474651412465441">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Vidi</surname><given-names>Keerthiga</given-names></name>
<xref ref-type="aff" rid="aff2-1474651412465441">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-1474651412465441"><label>1</label>Department of Endocrinology, Apollo Specialty Hospital, Madurai, India</aff>
<aff id="aff2-1474651412465441"><label>2</label>Department of Medicine, Apollo Specialty Hospital, Madurai, India</aff>
<author-notes>
<corresp id="corresp1-1474651412465441">Dr. Krishnan Swaminathan, Consultant Endocrinologist, Apollo Specialty Hospital, Lakeview Road, KK Nagar, Madurai, 625 020, India. Email: <email>k_swaminathan@hotmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>13</volume>
<issue>2</issue>
<fpage>80</fpage>
<lpage>84</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Quinolones are commonly used medications due to their broad spectrum of action and high oral bioavailability. However, clinicians should be aware of potential toxicities including hypoglycaemia and cardiac rhythm disturbances. We present a case of quinolone induced severe refractory hypoglycaemia in a diabetic patient on sulphonylurea. Clinicians should educate patients about the possible hypoglycaemic effects of quinolones and assess the risk benefit ratio prior to initiating treatment with this group of drugs.</p>
</abstract>
<kwd-group>
<kwd>Hypoglycaemia</kwd>
<kwd>therapeutics</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>March/April 2013</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="section1-1474651412465441">
<title>Abbreviations:</title>
<p>K<sub>ATP</sub> ATP sensitive potassium channels</p>
<p>GLUT 1 glucose transporter 1</p>
<p>DEC 1 differentiated embryo-chondrocyte expressed gene 1</p>
</sec>
<sec id="section2-1474651412465441" sec-type="cases">
<title>Case Report</title>
<p>A 50 year old gentleman was admitted to our hospital with a three day history of febrile illness, diarrhoea and a 6 hour history of profuse sweating associated with palpitations. Past history was significant for well controlled type 2 diabetes and hypertension. His medications list included gliclazide 80 mgs twice daily, vildagliptin 50 mgs once daily, metformin 500 mgs twice daily, telmisartan 40 mgs once daily, atorvastatin 10 mgs nocte and a recent prescription by his general practitioner for ofloxacin 400 mgs twice daily to treat the diarrhoeal illness. Clinical examination showed a profusely sweaty, tachycardic patient. Blood glucose at admission was 44 mgs/dl (2.4 mmol/l). The patient had already stopped all his diabetes medications on the morning of admission as he was well aware of “hypo symptoms”. The admitting physician continued with a course of intravenous ciprofloxacin to cover for suspected urosepsis, in addition to his antihypertensive medication and statin. Over the next 28 hours, he had persistent symptomatic refractory hypoglycaemia (41-72 mgs/dl, 2.3 – 4 mmol/l) despite being on continuous dextrose infusions (<xref ref-type="fig" rid="fig1-1474651412465441">Figure 1</xref>). Glucagon was not given due to lack of availability. Renal, liver function tests, serum cortisol, complete blood count, chest x-ray and malarial screen were all within normal limits. There was no reason to suspect intentional overdose or malicious intent. Finally, the “quinolone connection” was considered. Cessation of ciprofloxacin (red arrow), was followed by normalization of glucose levels within 24 hours (<xref ref-type="fig" rid="fig2-1474651412465441">Figure 2</xref>).</p>
<fig id="fig1-1474651412465441" position="float">
<label>Figure 1.</label>
<caption><p>Glucose chart showing persistent hypoglycaemia and the red arrow intervention (Glucose values in mg/dl)</p></caption>
<graphic xlink:href="10.1177_1474651412465441-fig1.tif"/>
</fig><fig id="fig2-1474651412465441" position="float">
<label>Figure 2.</label>
<caption><p> Gradual improvement in glucose levels followed by tapering and complete cessation of dextrose infusion</p></caption>
<graphic xlink:href="10.1177_1474651412465441-fig2.tif"/>
</fig>
</sec>
<sec id="section3-1474651412465441" sec-type="discussion">
<title>Discussion</title>
<p>Insulin, sulphonylureas and meglitinides can cause prolonged hypoglycaemia in the context of compromised physiological defenses. Renal impairment is a recognized risk factor for prolonged hypoglycaemia, especially in patients taking sulphonylureas. Patients with longer duration of diabetes, reduced oral intake and previous hypoglycaemic episodes seem to be at particular risk of prolonged hypoglycaemia with sulphonylureas, in the setting of end stage renal failure.<sup><xref ref-type="bibr" rid="bibr1-1474651412465441">1</xref></sup> Severe hypoglycaemia occurs more frequently with glibenclamide due to its longer duration of action and possible inappropriate insulin stimulation at lower glucose levels.<sup><xref ref-type="bibr" rid="bibr2-1474651412465441">2</xref></sup></p>
<p>If the cause of prolonged hypoglycaemia in a diabetic individual is not obvious, as in our case, it is vital to think laterally for other causes. Hormonal deficiencies, especially hypocortisolism<sup><xref ref-type="bibr" rid="bibr3-1474651412465441">3</xref></sup> and the possibility of co-existing endogenous hyperinsulinism in a diabetic patient should be considered in the appropriate setting.<sup><xref ref-type="bibr" rid="bibr4-1474651412465441">4</xref></sup> Causes of endogenous hyperinsulinism include insulinoma, non insulinoma pancreatogenous hypoglycaemia syndrome<sup><xref ref-type="bibr" rid="bibr5-1474651412465441">5</xref></sup> and insulin autoimmune hypoglycaemia.<sup><xref ref-type="bibr" rid="bibr6-1474651412465441">6</xref></sup> Accidental, surreptious or malicious hypoglycaemia should always be in the differential diagnosis.<sup><xref ref-type="bibr" rid="bibr7-1474651412465441">7</xref></sup></p>
<p>Finally, drugs other than diabetes medications and alcohol can cause prolonged hypoglycaemia. In a review of 448 studies, 2696 cases of hypoglycaemia were associated with 164 different drugs.<sup><xref ref-type="bibr" rid="bibr8-1474651412465441">8</xref></sup> The most common offenders were quinolones, pentamidine, quinine, beta blockers and angiotensin converting agents.</p>
<p>Quinolones are commonly used antibiotics, especially in patients with diabetes. Their appeal lies in the broad spectrum of antimicrobial activity and high oral bioavailability. However, caution is warranted as cardiac rhythm alterations and hypoglycaemia have been reported with their use,<sup><xref ref-type="bibr" rid="bibr9-1474651412465441">9</xref></sup> especially in patients with predisposing factors like cardiac illness, renal failure and concomitant therapies like sulphonylurea use.</p>
<p>Our patient had consulted his general practitioner for a diarrhoeal illness and was prescribed ofloxacin. While quinolone use is restricted in the western world due to fear of clostridium difficile infections, it is commonly used in the tropics in combination with anti-protozoal drugs, as a first line treatment for enteric infections. Three days later, he started to develop palpitations and profuse sweating episodes. The patient had noticed hypoglycaemic values on his glucometer and had stopped all his diabetes medications but continued to receive intravenous ciprofloxacin. Unfortunately, at the time of his</p>
<p>presentation, the “quinolone link” was missed. Only when the hypoglycaemia failed to improve in the absence of any other significant co-morbidities (renal or liver impairment, hypocortisolism and severe sepsis), did we think about drug interactions. A literature search alerted us to the possibility of quinolone induced hypoglycaemia.<sup><xref ref-type="bibr" rid="bibr10-1474651412465441">10</xref><xref ref-type="bibr" rid="bibr11-1474651412465441"/>–<xref ref-type="bibr" rid="bibr12-1474651412465441">12</xref></sup> In fact, central pontine myelinolysis and hypoglycaemia induced quadriplegia have been reported with levofloxacin use in a patient with type 2 diabetes, despite stopping insulin therapy three days prior to the first hypoglycaemic episode.<sup><xref ref-type="bibr" rid="bibr13-1474651412465441">13</xref></sup> Cessation of ciprofloxacin in our patient led to a dramatic improvement in glucose levels over the next 24 hours.</p>
<p>Both hyper and hypoglycaemias have been reported with fluroquinolone use. In a study of 17,108 patients receiving a fluroquinolone or ceftriaxone, alterations in glucose levels were much higher in those receiving gatifloxacin or levofloxacin than ceftriaxone.<sup><xref ref-type="bibr" rid="bibr12-1474651412465441">12</xref></sup> Although the exact molecular mechanisms of fluroquinolone induced hypoglycaemia is not completely clear, there is some evidence for fluroquinolones to cause hypoglycaemia by directly stimulating insulin release.</p>
<p>K<sub>ATP</sub> channels in the pancreatic beta cells are critical regulators of insulin secretion. Inhibition of these channels lead to a cascade of events that trigger insulin release. K<sub>ATP</sub> channel has two sub units, SUR 1 and kir 6.2. Gatifloxacin, temafloxacin and levofloxacin directly inhibit kir 6.2 subunit.<sup><xref ref-type="bibr" rid="bibr14-1474651412465441">14</xref></sup> In animal models, gatifloxacin and temafloxacin have been shown to inhibit K<sub>ATP</sub> channels with greater potency than levofloxacin, resulting in marked stimulation of insulin secretion.<sup><xref ref-type="bibr" rid="bibr15-1474651412465441">15</xref></sup></p>
<p>Quinolones may also have effects on other molecular mechanisms independent of insulin action. For example, gatifloxacin has been demonstrated to affect GLUT 1 gene transcription and such altered GLUT 1 function has been shown to cause hypoglycaemia.<sup><xref ref-type="bibr" rid="bibr16-1474651412465441">16</xref></sup> Finally, there is increasing attention on the role of DEC 1 (Differentiated embryo-chondrocyte expressed gene 1), a transcription factor that may play a vital role in metabolic diseases. There is evidence showing that DEC1 may have a role in adverse effects including hypoglycaemia caused by quinolone antibiotics.<sup><xref ref-type="bibr" rid="bibr17-1474651412465441">17</xref></sup></p>
</sec>
<sec id="section4-1474651412465441">
<title>Key messages</title>
<list id="list1-1474651412465441" list-type="bullet">
<list-item>
<p>Quinolones are commonly used drugs in patients with diabetes.</p></list-item>
<list-item>
<p>This class of drugs has the potential to cause severe hypoglycaemia, especially in combination with sulphonylurea</p></list-item>
<list-item>
<p>Physicians should have a high index of suspicion for the “quinolone link” in patients with unexplained severe refractory hypoglycaemia</p></list-item>
<list-item>
<p>Cessation of quinolone therapy usually results in a dramatic improvement in glucose levels</p></list-item>
</list>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other">
<label>Patient outcome</label>
<p>The patient was discharged two days after stopping ciprofloxacin. He was restarted on metformin and vildagliptin with no further hypoglycaemic episodes. He has been educated about this drug interaction so that such episodes can be avoided in the future.</p>
</fn>
<fn fn-type="other">
<label>Contributor statement</label>
<p>Dr.Krishnan Swaminathan was involved in the diagnosis, management and writing up of this manuscript. Dr.Keerthiga Vidi was involved in writing up the case report section of this manuscript.</p>
</fn>
<fn fn-type="conflict">
<label>Declaration of conflicting interests</label>
<p>The authors declare that there is no conflict of interest.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1474651412465441">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krepinsky</surname><given-names>J</given-names></name>
<name><surname>Ingram</surname><given-names>AJ</given-names></name>
<name><surname>Clase</surname><given-names>CM</given-names></name>
</person-group>. <article-title>Prolonged sulfonylurea-induced hypoglycaemia in diabetic patients with end-stage renal disease</article-title>. <source>Am J Kidney Dis</source> <year>2000</year>;<volume>35</volume>:<fpage>500</fpage>-<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr2-1474651412465441">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Szoke</surname><given-names>E</given-names></name>
<name><surname>Gosmanov</surname><given-names>NR</given-names></name>
<name><surname>Sinkin</surname><given-names>JC</given-names></name>
<name><surname>Nihalani</surname><given-names>A</given-names></name>
<name><surname>Fender</surname><given-names>AB</given-names></name>
<name><surname>Cryer</surname><given-names>PE</given-names></name>
<name><surname>Meyer</surname><given-names>C</given-names></name>
<name><surname>Gerich</surname><given-names>JE</given-names></name>
</person-group>. <article-title>Effects of glimepiride and glyburide on glucose counter regulation and recovery from hypoglycaemia</article-title>. <source>Metabolism</source> <year>2006</year>;<volume>55</volume>:<fpage>78</fpage>.</citation>
</ref>
<ref id="bibr3-1474651412465441">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cryer</surname><given-names>PE</given-names></name>
<name><surname>Axelrod</surname><given-names>L</given-names></name>
<name><surname>Grossman</surname><given-names>AB</given-names></name>
<name><surname>Heller</surname><given-names>SR</given-names></name>
<name><surname>Montori</surname><given-names>VM</given-names></name>
<name><surname>Seaquist</surname><given-names>ER</given-names></name>
<name><surname>Service</surname><given-names>FJ</given-names></name>
</person-group> <collab>Endocrine Society</collab>. <article-title>Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline</article-title>. <source>J Clin Endocrinol Metab</source> <year>2009</year>;<volume>94</volume>:<fpage>709</fpage>.</citation>
</ref>
<ref id="bibr4-1474651412465441">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cander</surname><given-names>S</given-names></name>
<name><surname>Gül</surname><given-names>OÖ</given-names></name>
<name><surname>Yıldırım</surname><given-names>N</given-names></name>
<name><surname>Unal</surname><given-names>OK</given-names></name>
<name><surname>Saraydarogğlu</surname><given-names>O</given-names></name>
<name><surname>Imamogğlu</surname><given-names>S</given-names></name>
</person-group>. <article-title>A rare cause of hypoglycaemia in a type 2 diabetic patient: insulinoma</article-title>. <source>J Diabetes Complications</source> <year>2012</year>;<volume>26</volume>:<fpage>65</fpage>-<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr5-1474651412465441">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>GB</given-names></name>
<name><surname>Service</surname><given-names>FJ</given-names></name>
<name><surname>Andrews</surname><given-names>JC</given-names></name>
<name><surname>Lloyd</surname><given-names>RV</given-names></name>
<name><surname>Natt</surname><given-names>N</given-names></name>
<name><surname>van Heerden</surname><given-names>JA</given-names></name>
<name><surname>Grant</surname><given-names>CS</given-names></name>
</person-group>. <article-title>Noninsulinoma pancreatogenous hypoglycaemia syndrome: an update in 10 surgically treated patients</article-title> <source>Surgery</source>. <year>2000</year>; <volume>128</volume>:<fpage>937</fpage>.</citation>
</ref>
<ref id="bibr6-1474651412465441">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lupsa</surname><given-names>BC</given-names></name>
<name><surname>Chong</surname><given-names>AY</given-names></name>
<name><surname>Cochran</surname><given-names>EK</given-names></name>
<name><surname>Soos</surname><given-names>MA</given-names></name>
<name><surname>Semple</surname><given-names>RK</given-names></name>
<name><surname>Gorden</surname><given-names>P</given-names></name>
</person-group>. <article-title>Autoimmune forms of hypoglycaemia</article-title>. <source>Medicine (Baltimore)</source> <year>2009</year>; <volume>88</volume>:<fpage>141</fpage> .</citation>
</ref>
<ref id="bibr7-1474651412465441">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marks</surname><given-names>V</given-names></name>
<name><surname>Teale</surname><given-names>JD</given-names></name>
</person-group>. <article-title>Hypoglycaemia: factitious and felonious</article-title>. <source>Endocrinol Metab Clin North Am</source> <year>1999</year>;<volume>28</volume>:<fpage>579</fpage>-<lpage>601</lpage>.</citation>
</ref>
<ref id="bibr8-1474651412465441">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Murad</surname><given-names>MH</given-names></name>
<name><surname>Coto-Yglesias</surname><given-names>F</given-names></name>
<name><surname>Wang</surname><given-names>AT</given-names></name>
<name><surname>Sheidaee</surname><given-names>N</given-names></name>
<name><surname>Mullan</surname><given-names>RJ</given-names></name>
<name><surname>Elamin</surname><given-names>MB</given-names></name>
<name><surname>Erwin</surname><given-names>PJ</given-names></name>
<name><surname>Montori</surname><given-names>VM</given-names></name>
</person-group>. <article-title>Clinical review: Drug-induced hypoglycaemia: a systematic review</article-title>. <source>J Clin Endocrinol Metab</source> <year>2009</year>;<volume>94</volume>:<fpage>741</fpage>-<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr9-1474651412465441">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pugi</surname><given-names>A</given-names></name>
<name><surname>Longo</surname><given-names>L</given-names></name>
<name><surname>Bartoloni</surname><given-names>A</given-names></name>
<name><surname>Rossolini</surname><given-names>GM</given-names></name>
<name><surname>Mugelli</surname><given-names>A</given-names></name>
<name><surname>Vannacci</surname><given-names>A</given-names></name>
<name><surname>Lapi</surname><given-names>F</given-names></name>
</person-group>. <article-title>Cardiovascular and metabolic safety profiles of the fluoroquinolones</article-title>. <source>Expert Opin Drug Sa</source>. <year>2012</year>;<volume>11</volume>:<fpage>53</fpage>-<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr10-1474651412465441">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Micheli</surname><given-names>L</given-names></name>
<name><surname>Sbrilli</surname><given-names>M</given-names></name>
<name><surname>Nencini</surname><given-names>C</given-names></name>
</person-group>. <article-title>Severe hypoglycaemia associated with levofloxacin in Type 2 diabetic patients receiving polytherapy: two case reports</article-title>. <source>Int J Clin Pharmacol The</source>. <year>2012</year>;<volume>50</volume>:<fpage>302</fpage>-<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr11-1474651412465441">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kelesidis</surname><given-names>T</given-names></name>
<name><surname>Canseco</surname><given-names>E</given-names></name>
</person-group>. <article-title>Quinolone-induced hypoglycaemia: a life-threatening but potentially reversible side effect</article-title>. <source>Am J Med</source> <year>2010</year>; <volume>123</volume>:<fpage>e5</fpage>-<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr12-1474651412465441">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mohr</surname><given-names>JF</given-names></name>
<name><surname>McKinnon</surname><given-names>PS</given-names></name>
<name><surname>Peymann</surname><given-names>PJ</given-names></name>
<name><surname>Kenton</surname><given-names>I</given-names></name>
<name><surname>Septimus</surname><given-names>E</given-names></name>
<name><surname>Okhuysen</surname><given-names>PC</given-names></name>
</person-group>. <article-title>A retrospective, comparative evaluation of hypoglycaemia in hospitalized patients receiving gatifloxacin, levofloxacin, ciprlevofloxacin, or ceftriaxone</article-title>. <source>Pharmacotherapy</source> <year>2005</year>;<volume>25</volume>:<fpage>1303</fpage>-<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr13-1474651412465441">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vallurupalli</surname><given-names>S</given-names></name>
<name><surname>Huesmann</surname><given-names>G</given-names></name>
<name><surname>Gregory</surname><given-names>J</given-names></name>
<name><surname>Jakoby</surname><given-names>MG</given-names><suffix>4th</suffix></name>
</person-group>. <article-title>Levofloxacin-associated hypoglycaemia complicated by pontine myelinolysis and quadriplegia</article-title>. <source>Diabet Med</source> <year>2008</year>;<volume>25</volume>:<fpage>856</fpage>-<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr14-1474651412465441">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Owens</surname><given-names>RC</given-names><suffix>Jr.</suffix></name>
</person-group> <article-title>Fluoroquinolone-associated hypoglycaemia: a tale of two toxicities</article-title>. <source>Pharmacotherapy</source> <year>2005</year>;<volume>25</volume>:<fpage>1291</fpage>-<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr15-1474651412465441">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saraya</surname><given-names>A</given-names></name>
<name><surname>Yokokura</surname><given-names>M</given-names></name>
<name><surname>Gonoi</surname><given-names>T</given-names></name>
<name><surname>Seino</surname><given-names>S</given-names></name>
</person-group>. <article-title>Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels</article-title>. <source>Eur J Pharmacol</source> <year>2004</year>;<volume>497</volume>:<fpage>111</fpage>-<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr16-1474651412465441">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ge</surname><given-names>TF</given-names></name>
<name><surname>Law</surname><given-names>PY</given-names></name>
<name><surname>Wong</surname><given-names>HY</given-names></name>
<name><surname>Ho</surname><given-names>YY</given-names></name>
</person-group>. <article-title>Gatifloxacin affects GLUT1 gene expression and disturbs glucose homeostasis in vitro</article-title>. <source>Eur J Pharmaco</source>. <year>2007</year>;<volume>573</volume>:<fpage>70</fpage>-<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr17-1474651412465441">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shi</surname><given-names>X</given-names></name>
<name><surname>Zheng</surname><given-names>Y</given-names></name>
<name><surname>Ma</surname><given-names>W</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Possible involvement of DEC1 on the adverse effects of quinolone antibiotics</article-title>. <source>Toxicolog</source>. <year>2010</year>;<volume>271</volume>:<fpage>1</fpage>-<lpage>4</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>